As an affiliate of Servier – and being the Center of Excellence of Antibodies – our strategic focus is to apply our streamlined and efficient antibody platform and capabilities –  in the discovery and early development of highly differentiated antibody therapeutics. Over the years, Servier Symphogen has demonstrated our ability to deliver unique antibodies and we have advanced a number of projects from target to lead and further into clinical phases. In June 2025, the pipeline comprised 60 projects, 36 of which were in clinical development (including ​14​ new molecular entities) and 24 in research. Please follow this link to Servier’s development pipeline.